GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Pre-Tax Income

Petros Pharmaceuticals (Petros Pharmaceuticals) Pre-Tax Income : $-8.94 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Petros Pharmaceuticals's pretax income for the three months ended in Mar. 2024 was $-2.16 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.94 Mil. Petros Pharmaceuticals's pretax margin was -155.72%.

During the past 5 years, Petros Pharmaceuticals's highest Pretax Margin was -115.06%. The lowest was -334.41%. And the median was -212.86%.


Petros Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Petros Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Pre-Tax Income Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
-33.16 -22.01 -8.99 -20.04 -8.16

Petros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.39 -2.55 -4.55 0.32 -2.16

Competitive Comparison of Petros Pharmaceuticals's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petros Pharmaceuticals's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Pre-Tax Income falls into.



Petros Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Petros Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-10.762+2.62+-0.536+0.515+0
=-8.16

Petros Pharmaceuticals's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-3.928+1.734+-0.12+0.152+-0.00099999999999989
=-2.16

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Petros Pharmaceuticals  (NAS:PTPI) Pre-Tax Income Explanation

Petros Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-2.163/1.389
=-155.72%

During the past 5 years, Petros Pharmaceuticals's highest Pretax Margin was -115.06%. The lowest was -334.41%. And the median was -212.86%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Petros Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley director 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman director, 10 percent owner
Jcp Iii Sm Aiv, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan officer: Chief Financial Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor officer: Pres. & Chief Comm. Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek officer: President, Timm Medical 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold officer: Prin. Acct. Off/Prin. Fin. Off 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726

Petros Pharmaceuticals (Petros Pharmaceuticals) Headlines

From GuruFocus

Petros Pharmaceuticals Announces Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 11-30-2022

Petros Pharmaceuticals Responds to Fraudulent Press Release

By PurpleRose PurpleRose 07-28-2022